Title: Intratumoral INTASYL™ self-delivering RNAi targeting PD-1 provides in vivo tumor control and mechanistic modulation of tumor microenvironment analogous to that of systemic anti-PD-1 antibody
Authors: Benjamin Cuiffo, et al.
Session Title: Immunomodulatory Agents and Interventions
Abstract Number: 1739
Fireside Chat with Dr. Gerrit Dispersyn
Date: Thursday, December 3, 2020
Time: 3:05 p.m. EST
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Poster Title: Combination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer
Authors: Benjamin Cuiffo, et. al. Abstract Number: 198
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Presenter: Dr. Gerrit Dispersyn Date and Time: September 16, 2020 at 11:30 a.m. EST
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Abstract number: 5745 Title: Intratumoral delivery of mPH-804 (TIGIT targeting INTASYL compound) inhibits tumor growth and confers an inflammatory tumor microenvironment Session Title: Immune Checkpoints 2 Presenter: Dr. Simon P. Fricker
* This will be the second of two AACR virtual annual meeting events being held in 2020 due to the COVID-19 pandemic
KOL Speaker: Professor Caroline Robert, M.D., Ph.D., Head of the Dermatology Unit at Gustave
Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University
Abstract number: e15206 Title: Intratumoral use of self-delivering RNAi to reprogram the tumor microenvironment and boost the antitumor response Presenter: Dr.Gerrit Dispersyn
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Presenter: Dr. Gerrit Dispersyn Date and Time: 1:00 p.m. CST Location: Free registration for the event is available (click here)
* This will be a virtual event in 2020 due to the COVID-19 pandemic
Abstract number: 1179 Title: Adoptive Cell Therapy don’t over engineer it; Alternatives to gene editing to improve cell-based therapeutics for the treatment of cancer Presenter: Dr.Simon P. Fricker
* This will be a virtual event in 2020 due to the COVID-19 pandemic